Zydus Lifesciences Ltd - Stock Valuation and Financial Performance

BSE: 532321 | NSE: ZYDUSLIFE | Pharmaceuticals & Drugs | Large Cap

Zydus Lifesciences Share Price

961.35 -32.70 -3.29%
as on 12-Apr'24 16:59

DeciZen - make an informed investing decision on Zydus Lifesciences

Overall Rating
Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Semi Strong

Zydus Lifesciences stock performance -

mw4me loader
P/E Ratio (CD):
32.53
Market Cap:
96,734.3 Cr.
52-wk low:
482.6
52-wk high:
1,031.3

Is Zydus Lifesciences Ltd an attractive stock to invest in?

1. Is Zydus Lifesciences Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Zydus Lifesciences Ltd is a good quality company.

2. Is Zydus Lifesciences Ltd undervalued or overvalued?

The key valuation ratios of Zydus Lifesciences Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Zydus Lifesciences Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Zydus Lifesciences Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Zydus Lifesciences:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Zydus Lifesciences Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 14.2%18%25.7%14.8%14%11.8%7.4%12.4%10%8.4%-
Value Creation
Index
0.30.61.30.30.20.1-0.30.1-0.1-0.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7,2248,6519,4279,37711,90513,16614,25314,40415,11017,23718,508
Sales YoY Gr.-19.8%9%-0.5%27%10.6%8.3%1.1%4.9%14.1%-
Adj EPS 7.711.318.914.417.418.211.922.520.117.429.6
YoY Gr.-46.8%67.9%-23.6%20.6%4.3%-34.5%89.5%-11%-13.5%-
BVPS (₹) 33.641.555.76885.4101.4101.3126.9166173.1187.3
Adj Net
Profit
7851,1531,9361,4781,7821,8591,2172,3072,0541,7562,973
Cash Flow from Ops. 9039941,8941,3129191,2822,9323,2942,1052,689-
Debt/CF from Ops. 32.71.345.96.22.71.420.4-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 10.2%7.7%6.5%14.1%
Adj EPS 9.5%-0.1%13.4%-13.5%
BVPS20%15.2%19.5%4.3%
Share Price 17.4% 23% 25.3% 90.9%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
24.63038.923.422.719.411.719.713.710.216.4
Op. Profit
Mgn %
16.620.324.720.323.922.719.623.62120.727
Net Profit
Mgn %
11.313.720.415.714.714.18.51614.210.416.1
Debt to
Equity
0.80.60.40.80.60.80.80.40.30.1-
Working Cap
Days
15515315817818521321010310710299
Cash Conv.
Cycle
666153638010110310182050

Recent Performance Summary

Return on Equity has increased versus last 3 years average to 16.40%

Net Profit is growing at healthy rate in last 3 years 13.42%

Sales growth is good in last 4 quarters at 17.73%

Sales growth has been subdued in last 3 years 6.54%

Latest Financials - Zydus Lifesciences Ltd.

Standalone Consolidated
TTM EPS (₹) 25.1 29.6
TTM Sales (₹ Cr.) 9,582 18,508
BVPS (₹.) 143.6 187.3
Reserves (₹ Cr.) 14,352 18,744
P/BV 6.69 5.13
PE 38.28 32.53
From the Market
52 Week Low / High (₹) 482.55 / 1031.30
All Time Low / High (₹) 5.53 / 1031.30
Market Cap (₹ Cr.) 96,734
Equity (₹ Cr.) 100.6
Face Value (₹) 1
Industry PE 48

Management X-Ray of Zydus Lifesciences:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Zydus Lifesciences

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales7,2248,6519,4279,37711,90513,16614,25314,40415,11017,237
Operating Expenses 6,0316,8977,0977,4729,05810,18711,47311,01811,93513,666
Manufacturing Costs1,0661,2821,5531,1301,8922,1552,4832,5032,5722,983
Material Costs2,4132,8142,6733,0653,6574,1414,2434,0944,7575,336
Employee Cost 9741,0971,1191,4851,6451,9032,1702,0702,1782,456
Other Costs 1,5781,7051,7521,7921,8641,9882,5772,3522,4292,890
Operating Profit 1,1931,7542,3301,9042,8472,9782,7803,3853,1753,572
Operating Profit Margin (%) 16.5%20.3%24.7%20.3%23.9%22.6%19.5%23.5%21.0%20.7%
Other Income 865711714713320911775391475
Interest 118685363111196342186127130
Depreciation 201287292373539599697670713723
Exceptional Items -17-10-300-10-364-205113-604
Profit Before Tax 9421,4462,0991,6152,3312,3821,4952,3992,8382,590
Tax 106259177129564530320194512588
Profit After Tax 8361,1861,9211,4861,7661,8521,1762,2062,3262,002
PAT Margin (%) 11.6%13.7%20.4%15.8%14.8%14.1%8.2%15.3%15.4%11.6%
Adjusted EPS (₹)7.911.218.914.517.318.111.520.843.819.4
Dividend Payout Ratio (%)23%21%17%22%20%19%30%17%6%31%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 3,4394,2525,6996,9608,74510,38610,37612,99217,00017,516
Share Capital 102102102102102102102102102101
Reserves 3,3374,1495,5976,8588,64210,28410,27312,89016,89717,415
Minority Interest14416913615619112931335193720542173
Debt2,2652,3342,1074,9455,1137,1477,0413,6803,6761,081
Long Term Debt1,3621,1508962,4682,5553,9503,2156103620
Short Term Debt9021,1841,2112,4772,5583,1973,8273,0713,3141,081
Trade Payables9111,0911,3081,5481,8881,9232,0442,2062,1382,125
Others Liabilities 1,2281,2027827161,2041,7642,0381,9941,8321,600
Total Liabilities 7,9879,04710,03214,32517,14122,51322,83422,81026,70024,494

Fixed Assets

Gross Block4,6645,1395,7678,1039,34915,70216,78217,34517,65118,344
Accumulated Depreciation1,5401,7862,0172,3462,8673,5394,5515,2125,4626,823
Net Fixed Assets3,1243,3523,7515,7576,48312,16412,23112,13312,18911,521
CWIP 8927989511,5431,5278377427837261,201
Investments 871544164357466747658303,2881,547
Inventories1,3681,5361,3371,8042,3852,6882,7893,2363,7193,413
Trade Receivables1,1341,5881,7472,2783,2063,9513,6633,1273,3404,417
Cash Equivalents 5496706391,5441,3155499658881,107573
Others Assets8359491,1929651,4791,6511,6801,8122,3311,823
Total Assets 7,9879,04710,03214,32517,14122,51322,83422,81026,70024,494

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 9039941,8941,3129191,2822,9323,2942,1052,689
PBT 9421,4462,0991,6122,3122,3821,4952,2855,2322,583
Adjustment 2693452503346245391,4741,163-2,117934
Changes in Working Capital -20-377272-411-1384-972264191-336-236
Tax Paid -173-387-646-238-602-675-303-345-675-592
Cash Flow From Investing Activity -438-465-864-2,872-974-4,239-1,012-725-1,0001,171
Capex -473-496-957-2,935-1,035-1,046-889-847-1,055-992
Net Investments -1-1116512-4,74629-39-2,8632,048
Others 36427858501,554-1521612,918115
Cash Flow From Financing Activity -529-351-9352,316521,885-1,528-2,548-868-4,400
Net Proceeds from Shares 000000098700
Net Proceeds from Borrowing 132-330-2371,4991011,808-786-2,568-674-841
Interest Paid -86-67-44-56-105-80-324-184-111-126
Dividend Paid -153-184-572-3270-358-715-2-372-267
Others -421230-821,19956514296-781289-3,166
Net Cash Flow -6417895756-3-1,07239122236-540
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)26.230.8538.6223.4722.519.3611.3218.8815.5111.6
ROCE (%)17.6723.2128.616.5218.5515.8910.0214.3815.313.64
Asset Turnover Ratio0.961.031.010.790.760.660.631.271.191.32
PAT to CFO Conversion(x)1.080.840.990.880.520.692.491.490.91.34
Working Capital Days
Receivable Days52566377849997434042
Inventory Days64605560647070384338
Payable Days119130164170171168171189167146

Zydus Lifesciences Ltd Stock News

Zydus Lifesciences Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Zydus Lifesciences on 12-Apr-2024 16:59 is ₹961.4.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 16:59 the market cap of Zydus Lifesciences stood at ₹96,734.3.
The latest P/E ratio of Zydus Lifesciences as of 12-Apr-2024 16:59 is 38.28.
The latest P/B ratio of Zydus Lifesciences as of 12-Apr-2024 16:59 is 6.69.
The 52-week high of Zydus Lifesciences is ₹1,031.3 and the 52-week low is ₹482.6.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Zydus Lifesciences is ₹9,582 ( Cr.) .

About Zydus Lifesciences Ltd

Cadila Healthcare Limited, a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API) and human formulations. The company’s shares are listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The company’s initiatives in the areas of research and development span across the pharmaceuticals value chain, including New Chemical Entities (NCE), biologics, vaccines, specialty and complex generic formulations and API process development. The company has a global presence and sells its products in the United States, India, Europe and emerging markets including countries in Latin America, Asia Pacific region and Africa. The company has a pool of modern, cost efficient and regulatory compliant manufacturing facilities which ensures continuous supply of high quality products at the most competitive prices to its customers across the globe.

Business area of the company

The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.

Business verticals / products

  • Human Health Formulations
  • Consumer Wellness
  • Animal Healthcare

Awards

2008-09:

  • The Company received the 'Social and Corporate Governance Awards 2008' in the 'Best Social Responsibility Practice' category presented by the BSE, NASSCOM Foundation and Times Foundation jointly.

2009-10:

  • Received the 'IMAI OE Award for the Pioneering and Paradigm Shifting Applications of OE in Tablet Manufacturing' by the KAIZEN Institute.
  • Received the 'Best-In-Class Manufacturing Award (Pharma Sector)' by Stars of the Industry Awards.

2010-11:

  • Declared the ‘Emerging Company of the Year’ by the Economic Times Awards for Corporate Excellence 2010.

2011-12:

  • Zydus Research Centre, Ahmedabad has achieved the full AAALAC accreditation for the fourth year in a row. It has also received accreditation from College of American Pathologists (CAP) upon completion of the inspection process. This accreditation was received in the first inspection itself.

2012-13:

  • The Gujarat Ecology Commission selected the Company for good ‘Environment-friendly Practices in Gujarat’. Zydus Research Centre won the Safety Award for the third consecutive year from Gujarat Safety Council.

2013-14:

  • Moraiya formulations facility was awarded the 'Gold Award - Pharma Sector, Mega Large Business' by The Economic Times and Frost & Sullivan for achieving operational excellence.

2014-15:

  • The Moraiya formulations facility was awarded the 'Green Manufacturing Award - Gold Category' by International Research Institute for Manufacturing.
  • The Baddi formulations facility was awarded 'Gold Certificate Merit' in IMEA - India Manufacturing Excellence Awards 2014 by The Economic Times in partnership with Frost & Sullivan.

2015-16:

  • It was awarded the Overall India Pharma Excellence Award and the India Pharma Innovation of the Year Award from the Department of Pharmaceuticals, Government of India.

2016-17:

  • Topical formulations facility received the ‘Silver Certificate of Merit’ from Frost & Sullivan at India Manufacturing Excellence Awards 2016.

2017-18:

  • The manufacturing sites at Moraiya, Baddi and Sikkim received the Silver medal at the National Award for Manufacturing Competitiveness (NAMC) by IRIM global.
  • API manufacturing facility at Ankleshwar Ank Unit I bagged a Silver at the Greentech Safety Award 2017 in recognition of its safety systems from the Greentech Foundation, Environment.

2018-19:

  • Moraiya formulations manufacturing facility received the Gold Award in the category of Pharma Sector, Large Business at the India Manufacturing Excellence Awards, 2018.

2019-20:

  • Cadila Healthcare Limited received CSIR Diamond Jubilee Technology Award for Discovery & Development of Saroglitazar in June 2019.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.